×
About 2,220 results

ALLMedicine™ Focal Segmental Glomerulosclerosis Center

Research & Reviews  832 results

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
https://clinicaltrials.gov/ct2/show/NCT02639260

May 20th, 2022 - Background. ManNAc (N-acetyl D-mannosamine) is an uncharged monosaccharide that is the biologic precursor of N-acetyl neuraminic acid (Neu5Ac, sialic acid). Sialic acids are the negatively charged, terminal monosaccharides of carbohydrate chains t...

Focal segmental glomerulosclerosis: Risk for recurrence and interventions to optimize o...
https://doi.org/10.1111/petr.14307
Pediatric Transplantation; Harshman LA, Bartosh S et. al.

May 20th, 2022 - FSGS is a common indication for kidney transplant with a high-risk of posttransplant recurrence. In this review, we summarize current knowledge about FSGS recurrence after kidney transplantation, including epidemiology, pretransplant planning, pos...

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
https://clinicaltrials.gov/ct2/show/NCT03493685

May 19th, 2022 - This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 300 study centers, globally. The...

Kidney Biopsy Features Most Predictive of Clinical Outcomes in the Spectrum of Minimal ...
https://doi.org/10.1681/ASN.2021101396
Journal of the American Society of Nephrology : JASN; Zee J, Liu Q et. al.

May 18th, 2022 - Heterogeneity in disease course and treatment response among patients with MCD/FSGS necessitates a granular evaluation of kidney tissue features. This study aimed to identify histologic and ultrastructural descriptors of structural changes most pr...

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
https://clinicaltrials.gov/ct2/show/NCT01613118

May 17th, 2022 - Focal segmental glomerulosclerosis (FSGS) is a rare glomerular disorder which results in frank proteinuria and progression to end-stage kidney disease (ESKD) over 5-10 years. Proteinuria reduction is widely regarded to be beneficial, and is consid...

see more →

Guidelines  2 results

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Impr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983378
Kidney International; Swanepoel CR, Atta MG et. al.

Feb 6th, 2018 - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulti...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  21 results

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
https://clinicaltrials.gov/ct2/show/NCT02639260

May 20th, 2022 - Background. ManNAc (N-acetyl D-mannosamine) is an uncharged monosaccharide that is the biologic precursor of N-acetyl neuraminic acid (Neu5Ac, sialic acid). Sialic acids are the negatively charged, terminal monosaccharides of carbohydrate chains t...

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
https://clinicaltrials.gov/ct2/show/NCT03493685

May 19th, 2022 - This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 300 study centers, globally. The...

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
https://clinicaltrials.gov/ct2/show/NCT01613118

May 17th, 2022 - Focal segmental glomerulosclerosis (FSGS) is a rare glomerular disorder which results in frank proteinuria and progression to end-stage kidney disease (ESKD) over 5-10 years. Proteinuria reduction is widely regarded to be beneficial, and is consid...

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
https://clinicaltrials.gov/ct2/show/NCT04387448

Mar 31st, 2022 - Approximately 125 patients will be enrolled in this study across the United States. Patients with DN and FSGS/TR-MCD will be randomized in 3 ascending dose cohorts to receive either GFB-887 or placebo.

Transformative Research in Diabetic Nephropathy
https://clinicaltrials.gov/ct2/show/NCT02986984

Mar 8th, 2022 - Progress in the area of diabetic kidney research leading to new therapeutics development has been very limited. Indeed, no new medicines indicated for the treatment of chronic kidney disease (CKD) have been approved since ARB's have become standar...

see more →

News  28 results

Nephrotic Syndrome Patients at High Risk of Kidney Failure, Vascular Problems
https://www.medscape.com/viewarticle/954056

Jul 1st, 2021 - NEW YORK (Reuters Health) - Adults with primary nephrotic syndrome (NS) had close to a 20 times greater risk of developing kidney failure and higher risks of several cardiovascular diseases and death compared to those without NS in a large analysi...

Protein Predicts Risk of AKI in COVID-19 Patients
https://www.medscape.com/viewarticle/939052

Oct 13th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Admission levels of a specific protein predict the development of acute kidney injury (AKI) as well as the need for dialysis in patients hospitali...

Late-onset neutropenia more common than expected in patients on rituximab
https://www.mdedge.com/rheumatology/article/228758/lupus-connective-tissue-diseases/late-onset-neutropenia-more-common
Steve Cimino

Sep 18th, 2020 - A new study has found that late-onset neutropenia is a notably common and occasionally serious occurrence in rituximab-treated patients with autoimmune diseases. Dr.

BRIEF-Vifor Pharma: VFMCRP And Chemocentryx Announce Topline Data From Phase-II Lumina-1 Trial Of CCX140 In Focal Segmental Glomerulosclerosis
https://www.reuters.com/article/brief-vifor-pharma-vfmcrp-and-chemocentr/brief-vifor-pharma-vfmcrp-and-chemocentryx-announce-topline-data-from-phase-ii-lumina-1-trial-of-ccx140-in-focal-segmental-glomerulosclerosis-idUSASN0006W6

May 18th, 2020 - May 18 (Reuters) - VIFOR PHARMA AG: * VFMCRP AND CHEMOCENTRYX ANNOUNCE TOPLINE DATA FROM PHASE-II LUMINA-1 TRIAL OF CCX140 IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Rituximab for Nephrotic Syndrome in Kids: A Note of Caution
https://www.medscape.com/viewarticle/904069

Feb 24th, 2020 - First-line Therapy for Nephrotic Syndrome: A Comparison Idiopathic nephrotic syndrome is the most common disorder of glomerular function in pediatrics.[1] Approximately 40% of children diagnosed with idiopathic nephrotic syndrome will have a relap...

see more →

Patient Education  1 results see all →